475830.KQ Orum Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:15
Feb 10
Feb 10
DAC degrader payload broadens ADC applications
Orum Therapeutics is developing DACs, which replace the cytotoxic ADC payload with a protein degrader. The degrader binds GSPT1 and E3 ligase, causing orderly cancer-cell death, can be recycled rather than used once, may have lower toxicity, and can address tumors that have become resistant to existing ADCs. Completed BMS and Vertex deals, strong cash position after financing, and a small market cap create asymmetric potential.
MED
About 475830.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 475830.KQ (Orum Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Noh Young-rae.